No profile data available.
Embecta Corp. (EMBC) is a healthcare company in the additional medication administration equipment industry, based in Parsippany, United States, with about 1,850 full-time employees.
It reported revenue of $1.08 billion for fiscal year 2025, down 3.8% from fiscal year 2024, and net income of $95.40 million. In Q3 2026 (the quarter ended June 30, 2026) revenue was $271.70 million, down 8.1% from a year before. United States was its largest region in fiscal year 2025, with 54% of revenue. Its market capitalization was $322.11 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended September 30, 2025; market data as of October 9, 2026.
, a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Embecta reported $1.08 billion in revenue for fiscal year 2025, down 3.8% from $1.12 billion in fiscal year 2024. In Q3 2026 revenue was $271.70 million.
United States: 54% of revenue by region in fiscal year 2025, followed by International (46%).
$322.11 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional medication administration equipment) include West Pharmaceutical Services, Inc. (WST), Stevanato Group S.p.A. (STVN), Retractable Technologies, Inc. (RVP), Biora Therapeutics, Inc. (BIOR).